Karen T. Liby

Karen T. Liby studies how specially designed small molecules can prevent or treat cancer, focusing on synthetic compounds such as triterpenoids and retinoid X receptor (RXR) agonists. Her work examines how these agents shape the tumor's surrounding immune environment and influence signaling pathways like NRF2/KEAP1, often using mouse models of lung, breast, skin, and NF1-associated cancers. A key theme is chemoprevention—stopping cancer before it fully develops—and combining these compounds with existing therapies.

Publication activity has been steady across most years with a sharp one-year spike in 2023, and recent output remains active at roughly 10 papers per year.

Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026

Typically publishes in teams of ~6 · 14% small-team papers (≤3 authors) · across 44 venues